Tectonic Therapeutic (NASDAQ:TECX) Shares Up 5.6% – Here’s What Happened

Posted by Geri Gentry on Aug 20th, 2026

Tectonic Therapeutic, Inc. (NASDAQ:TECX – Get Free Report)’s share price rose 5.6% on Tuesday . The company traded as high as $35.84 and last traded at $35.7450. Approximately 61,279 shares changed hands during trading, a decline of 77% from the average session volume of 266,883 shares. The stock had previously closed at $33.85.

Wall Street Analysts Forecast Growth

TECX has been the topic of several recent analyst reports. Raymond James Financial raised Tectonic Therapeutic from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $76.00 to $81.00 in a research note on Tuesday, May 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tectonic Therapeutic in a report on Friday, July 17th. Wall Street Zen upgraded Tectonic Therapeutic from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Zacks Research lowered Tectonic Therapeutic from a “hold” rating to a “strong sell” rating in a research report on Monday, July 20th. Finally, Wells Fargo & Company reduced their target price on Tectonic Therapeutic from $101.00 to $93.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Tectonic Therapeutic presently has a consensus rating of “Moderate Buy” and an average target price of $77.80.

View Our Latest Report on TECX

Tectonic Therapeutic Stock Performance

The company’s 50-day moving average price is $32.22 and its 200 day moving average price is $29.41. The stock has a market capitalization of $724.13 million, a PE ratio of -8.11 and a beta of 3.28.

Tectonic Therapeutic (NASDAQ:TECX – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($1.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.35) by $0.17. Analysts expect that Tectonic Therapeutic, Inc. will post -5.25 earnings per share for the current year.

Institutional Trading of Tectonic Therapeutic

Large investors have recently bought and sold shares of the company. AlphaCentric Advisors LLC raised its position in shares of Tectonic Therapeutic by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 6,849 shares of the company’s stock worth $212,000 after acquiring an additional 373 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of Tectonic Therapeutic in the 2nd quarter valued at approximately $34,000. Quantbot Technologies LP bought a new stake in shares of Tectonic Therapeutic during the second quarter valued at approximately $63,000. Wellington Management Group LLP boosted its position in shares of Tectonic Therapeutic by 7.5% during the second quarter. Wellington Management Group LLP now owns 31,432 shares of the company’s stock valued at $1,080,000 after purchasing an additional 2,192 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Tectonic Therapeutic by 24.3% in the first quarter. Bank of America Corp DE now owns 11,466 shares of the company’s stock worth $354,000 after purchasing an additional 2,241 shares during the period. 62.63% of the stock is owned by institutional investors.

Tectonic Therapeutic Company Profile

(Get Free Report)

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.